ライフサイエンスコーパス: non-Hodgkin lymphoma

1 a or small lymphocytic lymphoma; n=13 B-cell non-Hodgkin lymphoma).

2 -modulating agent with promising activity in non-Hodgkin lymphoma.

3 due to testicular cancer; and 829396 due to non-Hodgkin lymphoma.

4 atients with relapsed CD37-positive indolent non-Hodgkin lymphoma.

5 ome central to the evaluation of Hodgkin and non-Hodgkin lymphoma.

6 al for patients with relapsed CD37+ indolent non-Hodgkin lymphoma.

7 oma (FL) is the most common form of indolent non-Hodgkin lymphoma.

8 ) is the third most common subtype of B-cell non-Hodgkin lymphoma.

9 ombination is not being developed further in non-Hodgkin lymphoma.

10 classification, applies to both Hodgkin and non-Hodgkin lymphoma.

11 hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma.

12 umab in patients with relapsed or refractory non-Hodgkin lymphoma.

13 refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma.

14 vasculitis to glomerulonephritis and B-cell non-Hodgkin lymphoma.

15 ab in patients with relapsed indolent B-cell non-Hodgkin lymphoma.

16 studies of patients with relapsed/refractory non-Hodgkin lymphoma.

17 ell lymphoma (ALCL) is an aggressive CD30(+) non-Hodgkin lymphoma.

18 eloid leukaemia, and 0.940 (0.897-0.984) for non-Hodgkin lymphoma.

19 l nervous system lymphoma, and 7 (13%) other non-Hodgkin lymphoma.

20 fective as monotherapy for relapsed indolent non-Hodgkin lymphoma.

21 th previously untreated CD20-positive B-cell non-Hodgkin lymphoma.

22 ents with untreated, advanced stage indolent non-Hodgkin lymphoma.

23 hly active as initial treatment for indolent non-Hodgkin lymphoma.

24 athologically confirmed CD20-positive B-cell non-Hodgkin lymphoma.

25 r, kidney, prostate, and ovarian cancers and non-Hodgkin lymphoma.

26 uring the study period, 712 people developed non-Hodgkin lymphoma.

27 ced chronic lymphocytic leukaemia and B-cell non-Hodgkin lymphoma.

28 -cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

29 ll immune function is crucial for preventing non-Hodgkin lymphoma.

30 (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas.

31 ug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas.

32 heterogeneous and poorly understood group of non-Hodgkin lymphomas.

33 ents with relapsed and refractory aggressive non-Hodgkin lymphomas.

34 an uncommon yet devastating complication of non-Hodgkin lymphomas.

35 e Myeloma, 3 Chronic Lymphocytic Leukemia, 1 Non-Hodgkin Lymphoma, 1 Chronic Myeloid Leukemia, 2 Seve

36 tological (adjusted HR 1.94, 1.66-2.25, with non-Hodgkin lymphoma; 1.77, 1.50-2.09, with leukaemia; a

37 transplant recipients, SMRs were highest for non-Hodgkin lymphoma (10.7), kidney cancer (7.8), and me

38 lower risk), liver (18%-27% lower risk), and non-Hodgkin lymphoma (11%-18% lower risk in women).

39 s (Kaposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin lymphoma [11.51, 11.14-11.89], and cervix [3

40 sions, including 9 of 22 (41%) decisions for non-Hodgkin lymphoma, 16 of 76 (21%) for breast cancer,

41 5-year survival was 42% lower for secondary non-Hodgkin lymphoma, 19% for secondary breast carcinoma

42 % for AIDS-defining cancers (ADCs, including non-Hodgkin lymphoma, 2.0% of deaths) and 7.1% for non-A

43 oma) compared with primary CL (37% low-grade non-Hodgkin lymphoma, 27% extranodal marginal zone lymph

44 e additional patient was diagnosed as having non-Hodgkin lymphoma 3 months after the onset of CMV-ass

45 as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% a

46 splenomegaly was performed most commonly for non-Hodgkin lymphoma (48%) and myeloid metaplasia (31%).

47 4% [95% CI 72.9-73.9] vs 81.7% [81.3-82.1]), non-Hodgkin lymphoma (53.8% [53.3-54.4] vs 60.4% [60.0-6

48 were breast cancer (92 patients, 426 scans), non-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin d

49 were breast cancer (92 patients, 426 scans), non-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin d

50 unosuppression and HIV viraemia and risk for non-Hodgkin lymphoma, a common cancer in people living w

51 llicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma able to transform into germinal cen

52 lder patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissu

53 h Hodgkin lymphoma and one [10%] of ten with non-Hodgkin lymphoma; all responders had PD-L1 expressio

54 n anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis.

55 An EL4 mouse model of non-Hodgkin lymphoma and a B16 mouse model of subcutaneo

56 non-Hodgkin lymphomas or a combination of a non-Hodgkin lymphoma and a Hodgkin's lymphoma.

57 Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia sa

58 s is also associated with the development of non-Hodgkin lymphoma and cholangiocarcinoma (CCA).

59 t data regarding transplantation in indolent non-Hodgkin lymphoma and highlights the issues relevant

60 ver time in QOL among long-term survivors of non-Hodgkin lymphoma and identified demographic, clinica

61 stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL.

62 f this approach as a screening technique for non-Hodgkin lymphoma and melanoma skin cancer.

63 on of MYC-dependent B-cell neoplasms such as non-Hodgkin lymphoma and multiple myeloma.

64 ata raising concerns about associations with non-Hodgkin lymphoma and multiple myeloma.

65 iling data set including 249 cases of T-cell non-Hodgkin lymphoma and normal T cells.

66 tion among clinicians treating patients with non-Hodgkin lymphoma and stresses the need for cardiac m

67 gous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopres

68 in understanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnos

69 be at greater risk of childhood leukemia and non-Hodgkin lymphoma and those diagnosed with rob(13;14)

70 However, in many composite non-Hodgkin lymphomas and Hodgkin's lymphomas, the tumou

71 a or small lymphocytic lymphoma; n=10 B-cell non-Hodgkin lymphoma) and 22 in the dose-expansion cohor

72 dder, as well as leukemia, multiple myeloma, non-Hodgkin lymphoma, and breast cancer in postmenopausa

73 6-2012 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma, and cancer of the anus, liver, and

74 ays durable responses in relapsed/refractory non-Hodgkin lymphoma, and combination with rituximab and

75 standard first-line treatment for aggressive non-Hodgkin lymphoma, and doxorubicin and cyclophosphami

76 ng metastases in a murine xenograft model of non-Hodgkin lymphoma, and eliminated lymphoma in a xenog

77 rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1.5-6 h.

78 cidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and

79 analysis demonstrates that millions (liver, non-Hodgkin lymphoma, and melanoma) and billions (colore

80 teosarcoma, neuroblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma, and melanoma.

81 s apoptosis in acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.

82 loid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatm

83 ctions of Gilbert syndrome, Graves' disease, non-Hodgkin lymphoma, and various blood groups were accu

84 (MDS), myeloproliferative neoplasms (MPNs), non-Hodgkin lymphomas, and classical Hodgkin lymphoma.

85 renal cell cancers and most breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers rep

86 Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular adver

87 to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted.

88 Combined B-cell non-Hodgkin lymphomas are often clonally unrelated.

89 Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients

90 ectal cancer, leukaemia, thyroid cancer, and non-Hodgkin lymphomas are the most common cancers affect

91 toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel

92 Bone marrow showed clear non-Hodgkin lymphoma as the underlying disorder in 54% o

93 007 International Working Group criteria for non-Hodgkin lymphoma, assessed by an independent radiolo

94 mary effusion lymphoma (PEL) is a subtype of non-Hodgkin lymphoma associated with infection by Kaposi

95 ute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, a

96 olled study in adults with multiple myeloma, non-Hodgkin lymphoma (B- or T-cell), Hodgkin lymphoma, o

97 apsed/refractory B-cell malignancies such as non-Hodgkin lymphoma (B-NHL) or acute lymphoblastic leuk

98 ed phosphorylation may be involved in B-cell non-Hodgkin lymphoma (B-NHL) pathogenesis is largely unk

99 lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (B-NHL), which originates from germ

100 in the pathogenesis of many types of B-cell non-Hodgkin lymphoma (B-NHL).

101 ll transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL).

102 f chemotherapy-insensitive aggressive B-cell non-Hodgkin lymphoma (B-NHL).

103 B-cell non-Hodgkin lymphomas (B-NHL) represent the most common

104 We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protei

105 cts from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010.

106 IL-10R2 (n = 4) deficiency developed B-cell non-Hodgkin lymphoma between the ages of 5 and 6 years (

107 (prostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uterine, or cervical) from

108 CD27 is expressed on a majority of B-cell non-Hodgkin lymphoma, but its role in the immune control

109 cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovari

110 ld improve responses in patients with B-cell non-Hodgkin lymphoma, but our findings need confirmation

111 nt of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, but the mechanisms conferring resi

112 5 with potent antiproliferative activity in non-Hodgkin lymphoma cell lines.

113 sion of mantle cell lymphoma (MCL) and other non-Hodgkin lymphoma cells to lymphoma stromal cells con

114 cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma characterized by overexpression of

115 ntle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression

116 includes poor-risk rel/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy w

117 patients with relapsed or refractory kappa+ non-Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/C

118 or AIDS are at increased risk of Hodgkin and non-Hodgkin lymphoma compared with HIV-negative individu

119 Non-Hodgkin lymphoma comprises a variety of neoplasms, m

120 pproval of rituximab for treatment of B cell non-Hodgkin lymphoma, development of monoclonal antibodi

121 homas worldwide and approximately 30% of the non-Hodgkin lymphomas diagnosed in the United States.

122 matological neoplasms and ~20-25% of all new non-Hodgkin lymphoma diagnoses in western countries.

123 observational studies in adult patients with non-Hodgkin lymphoma (diffuse large B-cell lymphoma, fol

124 homa consists of mainly 4 subtypes of B-cell non-Hodgkin lymphoma: EMZL, FL, MCL, and DLBCL.

125 lymphoma (DLBCL), the most common subtype of Non-Hodgkin lymphoma, exhibits pathologic heterogeneity

126 pproximately 40% of patients with Hodgkin or non-Hodgkin lymphoma express the type II latency Epstein

127 mphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas frequently associated with poor pr

128 l, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011.

129 der, uterine, pancreatic, gastric cancer, or non-Hodgkin lymphoma from 2005 through 2013.

130 The resulting non-Hodgkin lymphoma gene sensor showed a detection limi

131 highly selective, label-free sensor for the non-Hodgkin lymphoma gene, with an aM detection limit, u

132 nfirmed CD20-positive relapsed or refractory non-Hodgkin lymphoma, had an Eastern Cooperative Oncolog

133 c leukaemia or relapsed or refractory B-cell non-Hodgkin lymphoma, had measurable disease, adequate o

134 Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting

135 The treatment of non-Hodgkin lymphomas has benefited enormously from the

136 mpts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective

137 spread adoption would substantially increase non-Hodgkin lymphoma health care costs.

138 doxorubicin) is a preferred regimen for HIV-non-Hodgkin lymphomas (HIV-NHLs), which are frequently E

139 cute lymphocytic leukemia, multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, myeloproliferati

140 myeloma (HR, 1.28 [95% CI, 1.01-1.62]), and non-Hodgkin lymphoma (HR, 1.16 [95% CI, >1.00-1.35]) can

141 dministration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable rem

142 mphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients </= 18 years of age.

143 ar lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere.

144 ymphoma (FL), the second most common type of non-Hodgkin lymphoma in the western world, is characteri

145 ular lymphoma (FL) is the second most common non-Hodgkin lymphoma in the Western world.

146 homa (FL) constitutes the second most common non-Hodgkin lymphoma in the western world.

147 c leukaemia; 560 mg for patients with B-cell non-Hodgkin lymphoma) in a standard 3 x 3 design until d

148 phoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse larg

149 Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable an

150 sion phase (n = 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemi

151 study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

152 py agent increasingly used to treat indolent non-Hodgkin lymphoma (iNHL).

153 a of the lung/bronchus (IRR, 1.58; P < .01), non-Hodgkin lymphoma (IRR, 1.41; P < .01), and breast ca

154 tion of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with p

155 Worldwide, B cell non-Hodgkin lymphoma is the most common hematological ma

156 ymphoma, the most common indolent subtype of non-Hodgkin lymphoma, is associated with a relatively lo

157 diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, do

158 cal HL was 5.3 (95% CI, 3.0 to 8.8), and for non-Hodgkin lymphoma, it was 1.9 (95% CI, 1.3 to 2.6).

159 atients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL).

160 sion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized predominantly in body cav

161 t was the sole key predictor of risk for CNS non-Hodgkin lymphoma (<50 cells per muL vs >=500 cells p

162 cer-attributable deaths were associated with non-Hodgkin lymphoma, lung cancer, and liver cancer.

163 tourinary cancers other than bladder cancer, non-Hodgkin lymphoma, lung cancer, leukaemia other than

164 In 15 non-Hodgkin lymphomas, many more sst2 sites were labeled

165 em; thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma; multiple myeloma; leukemia; and al

166 hronic lymphocytic leukemia (CLL; n = 41) or non-Hodgkin lymphoma (n = 145).

167 tAML risks increased after chemotherapy for non-Hodgkin lymphoma (n = 158; Poisson regression Ptrend

168 ing the study were attributed to progressive non-Hodgkin lymphoma (n = 2), treatment-related sepsis (

169 lastic lymphoma (n = 1, 6%), and unspecified non-Hodgkin lymphoma (n = 2, 11%).

170 s treated with CD19-directed CAR T cells for non-Hodgkin lymphoma (n = 23) and acute lymphoblastic le

171 , including acute leukemia (n = 591; 28.7%), non-Hodgkin lymphoma (n = 461; 22.3%), and myeloma (n =

172 , chronic lymphocytic leukemia (n = 24), and non-Hodgkin lymphoma (n = 62).

173 e myeloid leukemia (n=65), 39% in aggressive non-Hodgkin lymphoma (n=83), and 37% in indolent or mant

174 eloped a second malignancy during follow-up (non-Hodgkin lymphoma, n = 13; leukemia, n = 6; solid tum

175 nts, black recipients had lower incidence of non-Hodgkin lymphoma (NHL) (adjusted incidence rate rati

176 m melanoma (RR = 8.75; 95% CI: 1.89, 40.53), non-Hodgkin lymphoma (NHL) (RR = 2.69; 95% CI: 1.33, 5.4

177 d young adults with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) and compared the biodistribut

178 uding data on 1,427 incident cases of B-cell non-Hodgkin lymphoma (NHL) and its major subtypes identi

179 ate adjusted incidence rate ratios (aIRR) of non-Hodgkin lymphoma (NHL) and other cancers with increa

180 Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis

181 's syndrome (pSS) confers increased risk for non-Hodgkin lymphoma (NHL) development.

182 dioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy

183 mining prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years.

184 The association between benzene exposure and non-Hodgkin lymphoma (NHL) has been the subject of debat

185 Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and lim

186 ious studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of dev

187 Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosi

188 Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in

189 d T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified.

190 s (1987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transp

191 The incidence of non-Hodgkin lymphoma (NHL) in human immunodeficiency vir

192 Little is known about the risk of non-Hodgkin lymphoma (NHL) in nonsmokers who are exposed

193 s with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study.

194 The risk for non-Hodgkin lymphoma (NHL) is markedly increased in pers

195 Non-Hodgkin lymphoma (NHL) is the most common AIDS-defin

196 Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defin

197 Non-Hodgkin lymphoma (NHL) is the most commonly diagnose

198 Dietary fat intake may contribute to non-Hodgkin lymphoma (NHL) pathogenesis by influencing c

199 g of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) relative to antiretroviral th

200 ommon immune system-altering experiences and non-Hodgkin lymphoma (NHL) risk using a case-control stu

201 association of self-reported TFA intake with non-Hodgkin lymphoma (NHL) risk.

202 Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse l

203 a-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes.

204 le cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is incurable with standa

205 Patients with non-Hodgkin lymphoma (NHL) who are treated with rituxima

206 carcinoma, gastric cancer, Burkitt lymphoma, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma.

207 In non-Hodgkin lymphoma (NHL), objective response rates to

208 s and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refracto

209 In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construc

210 In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reacti

211 apsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged admin

212 eveloped Hodgkin lymphoma (HL), 38 developed non-Hodgkin lymphoma (NHL), three developed T-cell proly

213 represent attractive targets for therapy in non-Hodgkin lymphoma (NHL).

214 ytes is associated with an increased risk of non-Hodgkin lymphoma (NHL).

215 of a potential novel risk factor for B-cell non-Hodgkin lymphoma (NHL).

216 d blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

217 netic variations are associated with risk of non-Hodgkin lymphoma (NHL).

218 ral suspected environmental risk factors for non-Hodgkin lymphoma (NHL).

219 are well established for adult patients with non-Hodgkin lymphoma (NHL).

220 tivity of this agent in patients with B-cell non-Hodgkin lymphoma (NHL).

221 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

222 t of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

223 etween infection with GB virus-C (GBV-C) and non-Hodgkin lymphoma (NHL).

224 emotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL).

225 d with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL).

226 rvival rates for children with mature B-cell non-Hodgkin lymphoma (NHL); however, associated late eff

227 erapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma (NHL); however, relapse rates are h

228 signature defining aggressiveness in B-cell non-Hodgkin lymphomas (NHL) and assessed whether this si

229 osition to lymphoma (collectively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and c

230 nt activity of 22% to 68% in relapsed B-cell non-Hodgkin lymphoma(NHL).

231 Non-Hodgkin lymphomas (NHLs) are the most common cancer

232 Non-Hodgkin lymphomas (NHLs) make up the majority of lym

233 se (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leuk

234 ll lymphoma, peripheral T-cell lymphoma, and non-Hodgkin lymphoma not otherwise specified) that recei

235 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes.

236 neous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell.

237 Adult patients with B cell non-Hodgkin lymphoma or chronic lymphocytic leukemia wer

238 mposite lymphomas can be combinations of two non-Hodgkin lymphomas or a combination of a non-Hodgkin

239 emotherapy and a diagnosis of breast cancer, non-Hodgkin lymphoma, or gynecologic cancers.

240 HIV RNA (viral load) predictors of risk for non-Hodgkin lymphoma, overall and by subtype.

241 for acute lymphoid leukaemia (p<0.0001) and non-Hodgkin lymphoma (p<0.0001 in AYAs and p=0.023 in ch

242 e breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rec

243 the study funder for further development in non-Hodgkin lymphoma, partly because of longer durations

244 nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after (131)I-tositumomab r

245 for 130 tumors in 39 relapsed or refractory non-Hodgkin lymphoma patients by coupling SPECT/CT imagi

246 e list of bacteria that promote human B-cell non-Hodgkin lymphoma, possibly by the infection of pDCs

247 ell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poo

248 in relapsed or refractory peripheral T-cell non-Hodgkin lymphoma (PTCL).

249 A middle-aged man with non-Hodgkin lymphoma received chemotherapy and a stem ce

250 logically documented, CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab were enroll

251 Non-Hodgkin lymphoma represents a wide spectrum of illne

252 an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively eva

253 argets overexpressed in multiple myeloma and non-Hodgkin lymphoma, respectively.

254 of neuroendocrine tumors, neuroblastoma, and non-Hodgkin lymphoma, respectively.

255 Cancer incidence was higher for non-Hodgkin lymphoma (standardized incidence ratio (SIR)

256 rolled in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera Intern

257 we analyzed 11 consecutive German High-Grade Non-Hodgkin Lymphoma Study Group trials.

258 e-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the

259 randomisation scheme stratified by indolent non-Hodgkin lymphoma subtype, rituximab-refractory type,

260 esholds may require inclusion of homogeneous non-Hodgkin lymphoma subtypes to account for differences

261 hemodynamics, we characterized two exemplary non-Hodgkin lymphoma subtypes with comparable CD20 expre

262 s also demonstrated efficacy in other B-cell non-Hodgkin lymphoma subtypes, in particular mantle cell

263 egistries and allowed reporting on the major non-Hodgkin lymphoma subtypes.

264 g myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukem

265 urkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma that is almost uniformly associated

266 mphoma (NKTCL) is a rare, aggressive form of non-Hodgkin lymphoma that is generally incurable at more

267 ymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the b

268 Cutaneous T-cell lymphoma is a form of non-Hodgkin lymphoma that manifests initially in the ski

269 ll lymphoma (ALCL) is a CD30-positive T-cell non-Hodgkin lymphoma that morphologically resembles ALK-

270 pensity to transform to an aggressive B-cell non-Hodgkin lymphoma that underscores the importance of

271 LA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical re

272 eloid leukemia, myelodysplastic syndrome, or non-Hodgkin lymphoma, the three most common indications

273 e overall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain largely in

274 EBV-associated cancer, and CLL/SLL forms of non-Hodgkin lymphomas; these cancers were associated wit

275 ); melanoma; CNS (intracranial); colorectal; non-Hodgkin lymphoma; thyroid; soft-tissue sarcoma; ovar

276 ting in the PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas trial, iPET scans of 596 patients

277 ing in the "PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" trial were reanalyzed by applying

278 in heavily pretreated relapsed or refractory non-Hodgkin lymphoma warrants further investigation as a

279 o rituximab in patients with indolent B-cell non-Hodgkin lymphoma was tolerable but did not lead to i

280 rmine key independent predictors of risk for non-Hodgkin lymphoma, we assessed associations with time

281 Patients aged 18 years or older with B-cell non-Hodgkin lymphoma were eligible.

282 patients with relapsed CD37+ indolent B-cell non-Hodgkin lymphoma were included for RM dosimetry.

283 patients with relapsed/refractory aggressive non-Hodgkin lymphoma were randomized to GDP or DHAP; 87

284 y independent predictors of risk for overall non-Hodgkin lymphoma were recent CD4 count (ie, lagged b

285 accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar

286 Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate diseas

287 n often remains undiagnosed in patients with non-Hodgkin lymphoma who received first-line R-CHOP or C

288 Participants with aggressive non-Hodgkin lymphoma whose first-line therapy was guided

289 ell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma with poor outcomes in patients with

290 ients (age >/=18 years) with indolent B-cell non-Hodgkin lymphoma with stable disease or better lasti

291 Burkitt lymphoma is a rare and aggressive non-Hodgkin lymphoma with three classifications: endemic

292 DLBCL) is the most common aggressive form of non-Hodgkin lymphoma with variable biology and clinical

293 mphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accep

294 PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes on current ther

295 L) is the most frequently occurring indolent non-Hodgkin lymphoma, with generally favorable outcomes

296 tant independent roles in the development of non-Hodgkin lymphoma, with likely subtype heterogeneity.

297 rituximab-refractory patients with indolent non-Hodgkin lymphoma, with manageable toxicity, and is a

298 ymphoma (FL) represents more than 20% of all non-Hodgkin lymphomas worldwide and approximately 30% of

299 mphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, yet 40% to 50% of patients will ev

300 oma (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it remains only partially char